No patients died of prostate cancer. The 5-year overall survival was 90%.
Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025 ...
At a median follow-up of 19.6 months, the median PSA was 0.028 ng/mL. 18/100 patients developed biochemical recurrence, with a median time to recurrence of 10 months. The biochemical recurrence-free ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate ...
News-Medical.Net on MSN
Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
News-Medical.Net on MSN
Gene expression test identifies prostate cancer patients who benefit from hormone therapy
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback